-
Something wrong with this record ?
Fenretinide favorably affects mucins (MUC5AC/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction
D. Garić, JB. De Sanctis, DC. Dumut, J. Shah, MJ. Peña, M. Youssef, BJ. Petrof, F. Kopriva, JW. Hanrahan, M. Hajduch, D. Radzioch,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
POP90155
CIHR - Canada
NV16-32302A
MZ0
CEP Register
- MeSH
- Administration, Oral MeSH
- Cell Line MeSH
- Cystic Fibrosis complications genetics pathology MeSH
- Fenretinide administration & dosage MeSH
- Phospholipids metabolism MeSH
- Mucus metabolism MeSH
- Rats MeSH
- Arachidonic Acid metabolism MeSH
- Docosahexaenoic Acids metabolism MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- Mucin 5AC metabolism MeSH
- Mucin-5B metabolism MeSH
- Mice, Inbred CFTR MeSH
- Mice MeSH
- Lung drug effects metabolism pathology MeSH
- Pneumonia microbiology pathology prevention & control MeSH
- Pseudomonas Infections microbiology pathology prevention & control MeSH
- Pseudomonas aeruginosa pathogenicity MeSH
- Respiratory Mucosa cytology metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Cystic fibrosis (CF) is the most common genetic disease in Caucasians. CF is manifested by abnormal accumulation of mucus in the lungs, which serves as fertile ground for the growth of microorganisms leading to recurrent infections and ultimately, lung failure. Mucus in CF patients consists of DNA from dead neutrophils as well as mucins produced by goblet cells. MUC5AC mucin leads to pathological plugging of the airways whereas MUC5B has a protective role against bacterial infection. Therefore, decreasing the level of MUC5AC while maintaining MUC5B intact would in principle be a desirable mucoregulatory treatment outcome. Fenretinide prevented the lipopolysaccharide-induced increase of MUC5AC gene expression, without affecting the level of MUC5B, in a lung goblet cell line. Additionally, fenretinide treatment reversed the pro-inflammatory imbalance of fatty acids by increasing docosahexaenoic acid and decreasing the levels of arachidonic acid in a lung epithelial cell line and primary leukocytes derived from CF patients. Furthermore, for the first time we also demonstrate the effect of fenretinide on multiple unsaturated fatty acids, as well as differential effects on the levels of long- compared to very-long-chain saturated fatty acids which are important substrates of complex phospholipids. Finally, we demonstrate that pre-treating mice with fenretinide in a chronic model of P. aeruginosa lung infection efficiently decreases the accumulation of mucus. These findings suggest that fenretinide may offer a new approach to therapeutic modulation of pathological mucus production in CF.
Department of Biochemistry McGill University Montreal Quebec Canada
Department of Human Genetics McGill University Montreal Quebec Canada
Department of Medicine Division of Experimental Medicine McGill University Montreal Quebec Canada
Department of Pharmacology and Therapeutics McGill University Montreal Quebec Canada
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023189
- 003
- CZ-PrNML
- 005
- 20201214125442.0
- 007
- ta
- 008
- 201125s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bbalip.2019.158538 $2 doi
- 035 __
- $a (PubMed)31678518
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Garić, Dušan $u Department of Human Genetics, McGill University, Montreal, Quebec, Canada; Program in Infectious Diseases and Immunity in Global Health, McGill University Health Center, Montreal, Quebec, Canada.
- 245 10
- $a Fenretinide favorably affects mucins (MUC5AC/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction / $c D. Garić, JB. De Sanctis, DC. Dumut, J. Shah, MJ. Peña, M. Youssef, BJ. Petrof, F. Kopriva, JW. Hanrahan, M. Hajduch, D. Radzioch,
- 520 9_
- $a Cystic fibrosis (CF) is the most common genetic disease in Caucasians. CF is manifested by abnormal accumulation of mucus in the lungs, which serves as fertile ground for the growth of microorganisms leading to recurrent infections and ultimately, lung failure. Mucus in CF patients consists of DNA from dead neutrophils as well as mucins produced by goblet cells. MUC5AC mucin leads to pathological plugging of the airways whereas MUC5B has a protective role against bacterial infection. Therefore, decreasing the level of MUC5AC while maintaining MUC5B intact would in principle be a desirable mucoregulatory treatment outcome. Fenretinide prevented the lipopolysaccharide-induced increase of MUC5AC gene expression, without affecting the level of MUC5B, in a lung goblet cell line. Additionally, fenretinide treatment reversed the pro-inflammatory imbalance of fatty acids by increasing docosahexaenoic acid and decreasing the levels of arachidonic acid in a lung epithelial cell line and primary leukocytes derived from CF patients. Furthermore, for the first time we also demonstrate the effect of fenretinide on multiple unsaturated fatty acids, as well as differential effects on the levels of long- compared to very-long-chain saturated fatty acids which are important substrates of complex phospholipids. Finally, we demonstrate that pre-treating mice with fenretinide in a chronic model of P. aeruginosa lung infection efficiently decreases the accumulation of mucus. These findings suggest that fenretinide may offer a new approach to therapeutic modulation of pathological mucus production in CF.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kyselina arachidonová $x metabolismus $7 D016718
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a cystická fibróza $x komplikace $x genetika $x patologie $7 D003550
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a kyseliny dokosahexaenové $x metabolismus $7 D004281
- 650 _2
- $a fenretinid $x aplikace a dávkování $7 D017313
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a plíce $x účinky léků $x metabolismus $x patologie $7 D008168
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední CFTR $7 D018181
- 650 _2
- $a mucin 5AC $x metabolismus $7 D055271
- 650 _2
- $a mucin 5B $x metabolismus $7 D055257
- 650 _2
- $a hlen $x metabolismus $7 D009093
- 650 _2
- $a fosfolipidy $x metabolismus $7 D010743
- 650 _2
- $a pneumonie $x mikrobiologie $x patologie $x prevence a kontrola $7 D011014
- 650 _2
- $a pseudomonádové infekce $x mikrobiologie $x patologie $x prevence a kontrola $7 D011552
- 650 _2
- $a Pseudomonas aeruginosa $x patogenita $7 D011550
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a respirační sliznice $x cytologie $x metabolismus $7 D020545
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a De Sanctis, Juan B $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic; Institute of Immunology, Faculty of Medicine, Universidad Central de Venezuela, Bolivarian Republic of Venezuela.
- 700 1_
- $a Dumut, Daciana Catalina $u Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada; Program in Infectious Diseases and Immunity in Global Health, McGill University Health Center, Montreal, Quebec, Canada.
- 700 1_
- $a Shah, Juhi $u Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada; Program in Infectious Diseases and Immunity in Global Health, McGill University Health Center, Montreal, Quebec, Canada.
- 700 1_
- $a Peña, Maria Johanna $u Institute of Immunology, Faculty of Medicine, Universidad Central de Venezuela, Bolivarian Republic of Venezuela.
- 700 1_
- $a Youssef, Mina $u Department of Human Genetics, McGill University, Montreal, Quebec, Canada; Program in Infectious Diseases and Immunity in Global Health, McGill University Health Center, Montreal, Quebec, Canada.
- 700 1_
- $a Petrof, Basil J $u Meakins-Christie Laboratories, Translational Research in Respiratory Diseases Program, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
- 700 1_
- $a Kopriva, Francisek $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Hanrahan, John W $u Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
- 700 1_
- $a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Radzioch, Danuta $u Department of Human Genetics, McGill University, Montreal, Quebec, Canada; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic; Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada; Program in Infectious Diseases and Immunity in Global Health, McGill University Health Center, Montreal, Quebec, Canada. Electronic address: danuta.radzioch@mcgill.ca.
- 773 0_
- $w MED00005211 $t Biochimica et biophysica acta. Molecular and cell biology of lipids $x 1879-2618 $g Roč. 1865, č. 2 (2020), s. 158538
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31678518 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125441 $b ABA008
- 999 __
- $a ok $b bmc $g 1595508 $s 1113865
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 1865 $c 2 $d 158538 $e 20191031 $i 1879-2618 $m Biochimica et biophysica acta. Molecular and cell biology of lipids $n Biochem Biophys Acta $x MED00005211
- GRA __
- $a POP90155 $p CIHR $2 Canada
- GRA __
- $a NV16-32302A $p MZ0
- LZP __
- $a Pubmed-20201125